SQZ Biotechnologies announced that a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial. The company has decided to continue to enroll patients in the SQZ-AAC-HPV-101 clinical trial. The patient is a 61-year-old male with a history of metastatic HPV16+ rectal squamous cell carcinoma. The patient remains on study and the treatment has been well tolerated to date. The second and third patients have also been enrolled in the trial. The company has completed the dose-limiting toxicity period for the lowest-dose cohort. The Study Safety Committee recommends that the company enroll patients in the highest-dose cohort. The company anticipates initial clinical data from the highest-dose cohort by Q4.
Published first on TheFly
